SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-21-010013
Filing Date
2021-05-12
Accepted
2021-05-12 16:21:36
Documents
15
Period of Report
2021-05-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrtx-20210512.htm   iXBRL 8-K 76594
2 EX-99.1 exhibit991-mirati2013equit.htm EX-99.1 281906
  Complete submission text file 0001628280-21-010013.txt   554311

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20210512.xsd EX-101.SCH 2418
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20210512_cal.xml EX-101.CAL 710
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20210512_def.xml EX-101.DEF 1647
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20210512_lab.xml EX-101.LAB 24275
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20210512_pre.xml EX-101.PRE 12646
8 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20210512_htm.xml XML 10513
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 21915428
SIC: 2834 Pharmaceutical Preparations